Nasus Research Development from 2010 to 2025
| NSRX Stock | 7.79 0.29 3.87% |
Research Development | First Reported 2010-12-31 | Previous Quarter 335 K | Current Value 538.1 K | Quarterly Volatility 260.5 K |
Check Nasus Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nasus Pharma's main balance sheet or income statement drivers, such as Interest Expense of 35.2 K, Selling General Administrative of 599.7 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.0. Nasus financial statements analysis is a perfect complement when working with Nasus Pharma Valuation or Volatility modules.
Check out the analysis of Nasus Pharma Correlation against competitors. Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Nasus Stock Analysis
When running Nasus Pharma's price analysis, check to measure Nasus Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nasus Pharma is operating at the current time. Most of Nasus Pharma's value examination focuses on studying past and present price action to predict the probability of Nasus Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nasus Pharma's price. Additionally, you may evaluate how the addition of Nasus Pharma to your portfolios can decrease your overall portfolio volatility.